Software Monitoring for Kidney Cancer Side Effects
What You Need to Know Before You Apply
What is the purpose of this trial?
To determine if Carevive software, which monitors treatment-related toxicities and then generates self-care management plans for these symptoms, will be feasible to implement among patients with metastatic renal cell carcinoma (RCC). Additionally for collection of preliminary data on treatment-related toxicities, quality of life, distress level, and drug adherence.
Do I have to stop taking my current medications?
The trial protocol does not specify whether you need to stop taking your current medications. It seems likely that you can continue your current treatment, as the trial focuses on monitoring side effects of new therapies.
What safety data exists for the Carevive software in monitoring kidney cancer treatment side effects?
The provided research does not directly mention the Carevive software or its safety data. However, it discusses various electronic systems and methods for monitoring cancer treatment side effects, including real-time toxicity reporting and patient-reported outcomes. These systems aim to improve patient safety by early detection and management of side effects, which could be relevant to the goals of the Carevive software.12345
Is the treatment in the trial 'Software Monitoring for Kidney Cancer Side Effects' a promising treatment?
What data supports the idea that Software Monitoring for Kidney Cancer Side Effects is an effective treatment?
The available research shows that electronic systems for reporting and managing side effects of cancer treatment can be effective. For example, a study on an Internet-based system for breast cancer patients demonstrated that it helped patients manage side effects and maintain their quality of life. Patients could communicate symptoms from home, which allowed medical staff to monitor and confirm side effects, leading to better self-management. This suggests that similar software monitoring systems, like Carevive, could be effective for kidney cancer patients by helping them manage side effects and improve their overall treatment experience.12569
Are You a Good Fit for This Trial?
This trial is for adults over 18 with metastatic renal cell carcinoma who are starting oral targeted therapy or immunotherapy. They must be able to consent, read English, have an email or smart device for texts, and visit the Wilmot Cancer Center every 3-4 months. Breastfeeding women and those without internet access can't join.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants use Carevive software to report and manage side effects from oral targeted therapy or immunotherapy
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Carevive software
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Rochester
Lead Sponsor
National Cancer Institute (NCI)
Collaborator